Regulus dumps first-gen ADPKD treatment in favor of second iteration; Sutro joins BioNova in $200M deal

Regulus Therapeutics just finished dosing patients in toxicity studies for its second-generation autosomal dominant polycystic kidney disease (ADPKD) candidate RGLS8429.

Based on FDA discussions and data from a Phase Ib trial on original ADPKD candidate RGLS4326, Regulus is shifting away from the first-generation candidate and prioritizing...

Click to view original post